| Model Number |
3000TFX |
| Medical Device Problem Code |
Intravalvular regurgitation (4068)
|
| Health Effect - Clinical Code |
Dyspnea (1816)
|
| Date of Event |
07/30/2025
|
|
Type of Reportable Event
|
Serious Injury
|
|
Event or Problem Description
|
|
It was learned through implant patient registry and investigation that a patient with a 23mm 3000tfx aortic valve was explanted after an implant duration of 8 years, 6 months due to regurgitation.The patient presented with sob, swelling/edema, lightheaded, and fatigue.The explanted valve was replaced with a 21mm 11500a valve.The patient was in stable condition post procedure and discharged pod #8.Edwards lifesciences maintains an implant patient registry.This registry is a patient tracking mechanism for serialized edwards implantable devices (bioprosthetic heart valves and annuloplasty rings), rather than a true post-market surveillance registry.Through the registry, edwards is notified when these devices are implanted.In addition, patient and/or device status may be reported to the registry via the implantation data cards.The information is received from various sources (e.G.Surgeon, hospital, and patient family members) and is not received in the form of a conventional 'customer complaint'.The information reported may or may not be related to the edwards device.
|
| |
|
Additional Manufacturer Narrative
|
|
H11: additional manufacturer narrative: the investigation is still in progress; therefore, a conclusion has yet to be established.A supplemental report will be submitted accordingly upon investigation completion.Edwards will continue to review and monitor all reported events.Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed.
|
| |
|
Additional Manufacturer Narrative
|
|
H11: additional manufacturer narrative: updated sections h6 (investigation findings, investigation conclusions) regurgitation is a common manifestation of bioprosthetic valve and valved conduit dysfunction.Common intraoperative factors that may cause or contribute to acute post-procedural regurgitation include device distortion; device interaction with patient anatomy or other devices; leaflet damage, and incorrectly sized valve seated.Non-structural valve dysfunction (nsvd), endocarditis and/or thrombosis may also cause or contribute to acute post-procedural regurgitation.Complaints reported with regurgitation as the primary complaint code are not typically attributed to manufacturing-related nonconformances.There is no evidence to suggest a manufacturing defect caused or contributed to the reported event.Based on the information available, the most likely root cause is patient factors, including hld, dm, chemotherapy.The subject device is not available for evaluation as it was discarded.The device history record (dhr) review was completed, and this device passed all manufacturing and sterilization inspections prior to release for distribution.There were no issues identified that would have impacted this event.Edwards will continue to review and monitor all reported events.Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed.H11: corrected data: corrected section h6 (type of investigation).
|
| |
|
Search Alerts/Recalls
|
|